Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines.

Author information

Affiliations

  • 1. Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom; University of Bari "Aldo Moro", Bari, Italy; Solent NHS Trust, Southampton, United Kingdom; and Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York.
      Authors
    • Cortese S 1
    (1 author)
  • 2. University of Melbourne, Melbourne, Australia, and Murdoch Children's research Institute, Melbourne, Australia.
      Authors
    • Coghill D 2
    (1 author)
  • 3. Center for Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York, and Midwest Research Group, Washington University School of Medicine, St. Louis, Missouri.
      Authors
    • Mattingly GW 3
    (1 author)
  • 4. Attention Deficit/Hyperactivity Program and Developmental Psychiatry Program, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Medical Council, UniEduK, São Paulo, Brazil; and the Center for Research and Innovation in Mental Health, National Institute of Developmental Psychiatry, São Paulo, Brazil.
      Authors
    • Rohde LA 4
    (1 author)
  • 5. Lurie Center for Autism, Lexington, Massachusetts; Massachusetts General Hospital, Boston, Massachusetts; and Harvard Medical School, Boston, Massachusetts.
      Authors
    • Thom RP 5
    (1 author)
    • Show all (8)

ORCIDs linked to this article

Journal of the American Academy of Child and Adolescent Psychiatry, 28 Feb 2024, 63(7):663-665
https://doi.org/10.1016/j.jaac.2024.02.008 PMID: 38428579 

Abstract 

Despite decades of clinical use and a large body of evidence, the WHO continues to exclude methylphenidate for attention-deficit/hyperactivity disorder (ADHD) from its EML.1 The exclusion of methylphenidate has dire implications for millions of individuals with ADHD worldwide, especially those living in low and low-middle income countries (LMIC), where governmental decisions to make medicines available are contingent on EML listing.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.jaac.2024.02.008

Citations & impact 

This article has not been cited yet.

Impact metrics

Alternative metrics

Altmetric item for https://www.altmetric.com/details/160147152
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/160147152

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.